ASH:青少年患者应采用儿童霍奇金淋巴瘤治疗方案
发布时间:2011-12-27 | 来源:爱唯医学网
关键词:
儿童霍奇金淋巴瘤
治疗
ABVE-PC方案
ABVE方案
据美国血液病学会(ASH)年会报告的一项研究结果,青少年霍奇金淋巴瘤患者采用儿童治疗方案,可获得较高应答率和持续缓解,且长期毒性可能低于成人治疗方案。
目前尚没有被普遍接受的青少年霍奇金淋巴瘤患者标准治疗方案,各治疗中心采用不同的成人或儿童治疗方案,罕有专门针对青少年患者治疗方案的研究数据发表。为此,伊利诺伊大学小儿科的Karen S. Fernandez博士及儿童肿瘤协作组(COG)同事对COG P9425和P9426研究中年龄<15岁儿童和15~20岁青少年患者的治疗情况进行了回顾性分析,以期在最大可能治愈率与降低长期毒性之间寻找平衡点。
P9425研究考察ABVE-PC方案(阿霉素+博来霉素+长春新碱+依托泊苷+泼尼松+环磷酰胺,剂量密集化疗)对晚期霍奇金淋巴瘤患者的疗效,而P9426研究则评价ABVE方案(阿霉素+博来霉素+长春新碱+依托泊苷,剂量密集化疗)对早期患者的疗效。P9425组快速早期应答患者在3个周期化疗后接受21 Gy放疗,而缓慢应答患者在7个周期化疗后接受相同剂量的放疗。P9426组早期应答患者在2个周期化疗后接受25 Gy放疗,其他患者则在4个化疗周期后接受相同剂量放疗。此外,研究者可根据患者情况自主确定是否添加右雷佐生治疗。
表 患者特征

结果显示,接受两种方案治疗的青少年和儿童患者5年无事件生存率分别为 85.9%和87.0%,10年无事件生存率分别为77.3%和83.8%(P=0.515)。与其他接受成人方案治疗、有标准或高至中度风险的霍奇金淋巴瘤的青少年患者研究相比,5年无事件生存率相似,但累计化疗剂量均显著降低,烷化剂、蒽环类以及依托泊苷累计剂量低于出现明显长期毒性的阈剂量。这些成人治疗方案包括BEACOPP方案(博来霉素+依托泊苷+阿霉素+环磷酰胺+长春新碱+泼尼松+甲基苄肼)、COPP-ABVD方案(BEACOPP+长春花碱+达卡巴嗪)和ABVD方案(阿霉素+博来霉素+长春花碱+达卡巴嗪)。此外,多因素分析结果显示,性别、组织学亚型和肿瘤分期均对预后无预测意义。
图 AYA患者与采用P9425及P9426治疗的HL儿童的无事件生存比较
研究者指出,鉴于减少长期毒性对青少年霍奇金淋巴瘤患者,尤其是晚期患者的生活质量改善非常重要,基于上述数据,赞成对这些患者采用限制剂量的儿童治疗方案。研究者承认该研究的局限性在于其回顾性试验设计和较小样本量(P9425和 P9426研究分别为104 例和 99 例)。此外,两项研究设计均未对儿童和青少年分别进行观察。研究者计划与成人肿瘤组合作,对青少年标准化治疗进行研究。
会议主持人、罗彻斯特大学血液肿瘤科主任Jonathan Friedberg博士指出,毒性反应并非完全取决于药物。儿童治疗方案似乎更加关注减少化疗剂量,以降低后期毒性,但普遍认为放疗可能是后期毒性的最主要原因,这一现象在上述晚期患者放疗方案中有所显现。Fernandez博士承认上述受试患者均接受放疗,但在目前进行的研究中,将根据第1个化疗周期后PET扫描结果判定患者应答情况,再确定患者是否接受放疗。
更多阅读
BEACOPP化疗治疗儿童及青少年高危霍奇金淋巴瘤疗效佳
研究摘要
Survival in Adolescents and Young Adults with Hodgkin Lymphoma Treated with Response-Based Chemotherapy on P9425 and P9426 Protocols:A Report From the Children’s Oncology Group
BACKGROUND
Hodgkin Lymphoma (HL) is a highly curable malignancy affecting all age groups with a bimodal distribution with peaks between the 2nd and 3rd decade of life and at over 60 years of age. Children and adolescents with HL treated according to recent Pediatric Oncology Group (POG) regimens received dose dense, response-based chemotherapy with low dose radiation, decreasing both cumulative doses of chemotherapy and radiation. Treatment of adolescents and young adults (AYA) has not been consistent, with choice of adult vs. pediatric regimens depending on the referral pattern and institutional polices.
The German Cooperative group reported equivalent results in the AYA group vs. adults using an adult focused protocol that included high dose alkylator therapy and high dose radiation, and used that data to recommend adult therapy for AYA. We evaluated the outcome of Pediatric vs. AYA patients in two POG trials to assess the utility of pediatric regimens for AYA HL.
PURPOSE AND METHODOLOGY
We retrospectively analyzed POG studies P9425 and P9426 to compare the survival rate of children (< 15 year of age) and AYA ( 15 – 20 years of age) with HL.
P9425 included 216 patients (104 AYA) with intermediate (IB, IIA/IIIA1 with large mediastinal adenopathy or IIIA2) or high-risk (IIB, IIIB, IV) biopsy-proven classical HL. A response-based treatment approach administered doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide (ABVE-PC) every 21 days. Rapid early responders (RER) to 3 ABVE-PC cycles received 21 Gy radiation to involved regions. Slow early responders (SER) received 2 additional ABVE-PC cycles before 21 Gy radiation. As previously published, this dose dense regimen resulted in excellent event-free and overall survival (EFS, OS) regardless of the risk assignment and early response. Five-year EFS 84%; 86% for RER, 83% for SER (P= 0 .85). Five-year OS was 95%.
P9426 study included 255 patients, (99 AYA) with low risk (Stage IA, IIA and IIIA) biopsy-proven HL. Chemotherapy was a response-based approach that utilized doxorubicin, bleomycin, vincristine and etoposide (ABVE) every 28 days. RER to 2 DBVE cycles received 25.5 Gy involved field irradiation. SER received 2 additional cycles of ABVE followed by irradiation. The 5-year EFS for early stage HL under this protocol was 87.8%. 5-year OS was 97.6%.
RESULTS
Of 471 eligible patients treated on POG 9425 and 9426, 203 were AYA. Table 1 shows patient characteristics. Male to female ratio was similar in both groups. The most common histology in both groups was nodular sclerosing. Mixed cellularity and lymphocyte predominant subtypes were more common in children less than 15 years of age. There was no difference in EFS for the younger vs. older patients. Figure 1.
CONCLUSIONS
The outcome of adolescents treated on P9425 and P2496 with dose dense, response-based treatment and reduced dose irradiation was not different from the outcome of children less than 15 years of age. The cumulative doses of alkylators, anthracyclines, and epipodophyllotoxins used in these pediatric protocols are below thresholds usually associated with significant long-term toxicity.
These data validate our preference for the treatment AYA and adolescents with HL using pediatric-focused therapy. This approach may reduce the risk for late adverse effects (cardiotoxicity, infertility, secondary malignancy) by limiting cumulative doses of alkylator agents, anthracyclines and radiation therapy. A focus on dose-limited regimens is critically important for younger patients (pediatric and AYA) who are expected to have long-term survival.